Genomic imprinting involves a DNA methylationedependent and parent-of-originespecific regulation of gene expression. Clinical assays for imprinting disorders are genomic locus, disorder, and molecular defect specific. We aimed to clinically validate a genome-wide approach for simultaneous testing of common imprinting disorders in a single assay. Using genome-wide DNA methylation arrays, epigenetic profiles from peripheral blood of patients with Angelman, Prader-Willi, Beckwith-Wiedemann, or SilverRussell syndromes were compared to a reference cohort of 361 unaffected individuals. The analysis was of developmental delay and intellectual disabilities. This approach has allowed 100% sensitivity and specificity in detecting imprinting defects in all 28 patients and enabled identification of defects beyond the classically tested imprinted loci. Analysis of the cohort of patients with developmental delay and intellectual disabilities identified two patients with Prader-Willi syndrome, one with BeckwithWiedemann syndrome, and several other patients with DNA methylation defects in novel putative imprinting loci. These findings demonstrate clinical validation of a sensitive and specific genome-wide DNA methylation arrayebased approach for molecular testing of imprinting disorders to allow simultaneous assessment of genome-wide epigenetic defects in a single analytical procedure, enabling replacement of multiple locus-specific molecular tests while allowing discovery of novel clinical epigenomic associations and differential diagnosis of other epigenomic disorders. (J Mol Diagn 2017, 19: 848e856; http://dx.doi.org/10.1016 /j.jmoldx.2017 Genomic imprinting refers to parent-of-originespecific gene expression. Most mammalian autosomal genes are expressed from both maternally and paternally inherited alleles, although it is well recognized that some genes are expressed from only one of the parentally inherited chromosomes. The choice of which of the two inherited copies is expressed is not random and results from reversible modifications of gene activity by epigenetic mechanisms.
1 A key epigenetic mechanism involved in the establishment and maintenance of genomic imprinting results from allelespecific cytosine methylation within the CpG dinucleotides of the genomic DNA at the imprinting control regions (ICRs).
2 Altered CpG methylation at these regions can result in deregulation of imprinted gene expression and has been associated with a group of medical conditions, including Angelman syndrome (AS), Prader-Willi syndrome (PWS), Beckwith-Wiedemann syndrome (BWS), and Silver-Russell syndrome (SRS). The mechanisms that result in altered imprinted gene expression are diverse, with the phenotype depending on the parental origin of the inherited defect. For example, imprinting defects can result from cytogenetic rearrangements (duplications and deletions), mutations in coding regions, epimutations, or uniparental disomy (UPD). UPD refers to meiotic or, in cases of somatic mosaicism, mitotic inheritance of both homologs of a chromosome or chromosomal region from only one parent. 4 Thus, when UPD occurs in chromosomal regions that include imprinted genes, the cells inherit two active (expressed parental) or two silent (repressed parental) alleles, leading to the abnormal transcriptional dosage of the imprinted genes.
AS and PWS are two classic neurologic disorders that result from imprinting defect at chromosome 15q11.2-q13. PWS results from hypermethylation of the 15q11.2-q13 critical region and/or the associated loss of the paternally expressed genes (including SNRPN ), whereas AS results from a loss of imprinting (hypomethylation) and/or loss of the maternally expressed UBE3A gene. The causal molecular mechanisms in PWS and AS include microdeletions, point mutations, translocations, UPD, and imprinting defects. Apart from point mutations in the maternally expressed UBE3A gene, which may cause AS in approximately 10% of cases, 5 all other known mechanisms that cause PWS and AS affect DNA methylation at the ICR on chromosome 15. SNURF/SNRPN is one of the paternally expressed loci in this region, and its parent-of-origine specific methylation has long been recognized as a diagnostic indicator of PWS and AS.
Other well-defined imprinting disorders include BWS and SRS. In most cases, these syndromes are caused by dysregulation of imprinted genes associated with cell cycle and growth control that are clustered in the 11p15.5 chromosome region.
6 Two important ICRs have been identified in this region: the H19/IGF2 domain (ICR1), which is methylated in the paternal allele, and the KCNQ1OT1/CDKN1C domain (ICR2), which is methylated in the maternal allele.
7
Genetic alterations that result in biparental IGF2 expression is one of the causes of BWS, whereas a loss of methylation of the paternally inherited imprinting center H19 results in biallelic H19 expression and silencing of IGF, thereby causing SRS. The genetic causes of imprinting defects within the 11p15.5 cluster are complex and involve molecular alterations that range from point mutations acting in cis to frameshift mutation acting in trans.
8 A subgroup of patients with BWS also had hypomethylation at other imprinted loci, 9 suggesting that genes other than those located at 11p15.5 may be involved in the pathogenesis of this syndrome. In addition, 10% of SRS cases are caused by maternal UPD7, including the known imprinted loci GRB10, SGCE/PEG10, and PEG/MEST.
10
The genetic, multilocus complexity of imprinted disorders makes them difficult to diagnose in a single analytic procedure. Identification of differential DNA methylation at imprinted regions is essential for the specific diagnosis of imprinting disorders. CpG islands within promoters and ICRs of imprinted genes are methylated on the silent allele and unmethylated on the active allele.
11 The classic approaches used in the diagnostic clinical laboratories involve multiple single-gene/locus DNA methylation assays for each imprinting defect. Our laboratory has developed a genome-wide methylation array (GWMA) analysis as an alternative approach to detect methylation defects across imprinted regions genome-wide and to provide simultaneous genomic methylation assessment for patients referred for genetic testing. We describe the validation of a clinical GWMA test to detect a broad spectrum of imprinting disorders. In addition to the specific imprinted locus, the genome-wide analysis allows comprehensive and simultaneous assessment of imprinting disorders, along with other single locus and genome-wide epigenetic defects in a single analytical procedure.
Materials and Methods
Sample Collection, DNA Extraction, and Genotyping
Samples from patients referred for genetic testing at Greenwood Genetic Center and at Hamilton Health Sciences were collected for methylation study. Genomic DNA was extracted from peripheral blood using standard techniques, and mutation analysis was performed according to standard practices by the Molecular Diagnostic Laboratory at the corresponding center. Patients with a previous molecular diagnosis of imprinting disorder, including PWS, AS, BWS, and SRS, were selected for the methylation study. Deidentified and anonymized DNA samples from patients undergoing diagnostic testing at Greenwood Genetic Center were provided for this study and do not require consent on the externally provided, anonymized, and deidentified DNA samples. For the cohort of patients with developmental and intellectual disabilities, this study has been approved by the Western University Research Ethics Boards and the Hamilton Integrated Research Ethics Board.
